A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

November 26, 2020

Study Completion Date

December 23, 2020

Conditions
Coronavirus Infections
Interventions
DRUG

Opaganib

Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).

DRUG

Placebo

Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).

Trial Locations (9)

12208

Albany Medical Center, Albany

33176

Miami Cancer Institute, Miami

48202

Henry Ford Hospital, Detroit

48236

Ascension St. John Hospital, Detroit

77089

Memorial Herman Southeast Hospital, Houston

77204

Memorial Hermann, Memorial City Medical Center, Houston

85258

HonorHealth Research Institute, Scottsdale

97239

Oregon Health & Science University, Portland

Unknown

Ziv Medical Center, Safed

All Listed Sponsors
lead

RedHill Biopharma Limited

INDUSTRY

NCT04414618 - A Study of Opaganib in Coronavirus Disease 2019 Pneumonia | Biotech Hunter | Biotech Hunter